期刊
GEBURTSHILFE UND FRAUENHEILKUNDE
卷 81, 期 5, 页码 539-548出版社
GEORG THIEME VERLAG KG
DOI: 10.1055/a-1464-1221
关键词
advanced breast cancer; biomarkers; therapy; prognosis
资金
- Hexal
- Pfizer
- Lilly
- Novartis
- Daiichi-Sankyo
- Merrimack
- Eisai
- PRAEGNANT network - Pfizer
- AstraZeneca
- MSD
- onkowissen.de
Recent studies have highlighted advancements in patient treatment and biomarkers in breast cancer, with new oral taxanes and clinical trial results for different molecular subtypes. Additionally, research on biomarkers for CDK4/6 inhibitors and the development of new substances for HER2+ breast cancer have shown promising progress.
This review summarises and discusses significant aspects of recently published studies on patient treatment in advanced breast cancer and on biomarkers in breast cancer. In recent years, a large number of drugs for all molecular subtypes have been developed up to phase III trials. With regard to immune checkpoint inhibitors in metastasised breast cancer, the recent discussion has centred on the best candidate for combined chemotherapy. The oral taxanes could become a new type of oral chemotherapies. There is a growing body of data on biomarkers for the use of CDK4/6 inhibitors, which could also signify further development for other molecular subtypes. New substances have been developed for metastatic HER2+ breast cancer that still result in good remission even after massive prior treatment and/or cerebral metastasis. Similarly, knowledge is growing about targeted therapies with antibody-drug conjugates (ADC) against Trop-2, which could bolster our therapeutic armoury in triple-negative breast cancer (TNBC). In addition, the clinical focus is on understanding how to maintain fertility after breast cancer treatment. Here, pooled analyses provide new insights.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据